Compounds > ruboxistaurin
Page last updated: 2024-09-04

ruboxistaurin and alvocidib

ruboxistaurin has been researched along with alvocidib in 5 studies

Compound Research Comparison

Studies
(ruboxistaurin)		Trials
(ruboxistaurin)		Recent Studies (post-2010)
(ruboxistaurin)		Studies
(alvocidib)		Trials
(alvocidib)		Recent Studies (post-2010) (alvocidib)
203295662766204

Protein Interaction Comparison

ProteinTaxonomyruboxistaurin (IC50)alvocidib (IC50)
Chain A, Protein (glycogen Phosphorylase)Oryctolagus cuniculus (rabbit)1
Glycogen synthase kinase-3 beta Sus scrofa (pig)0.36
[Tau protein] kinase Sus scrofa (pig)0.36
Cyclin-T1Homo sapiens (human)0.0243
Cyclin-KHomo sapiens (human)1.37
Serine/threonine-protein kinase D3Homo sapiens (human)8
G2/mitotic-specific cyclin-B2Homo sapiens (human)0.1571
G1/S-specific cyclin-E2Homo sapiens (human)0.36
Glycogen phosphorylase, muscle formOryctolagus cuniculus (rabbit)1.2
Epidermal growth factor receptorHomo sapiens (human)7.6
Vitamin K-dependent protein CHomo sapiens (human)0.1429
Protein kinase C gamma typeHomo sapiens (human)8
Protein kinase C beta typeHomo sapiens (human)8
Tyrosine-protein kinase LckHomo sapiens (human)0.4
Cyclin-dependent kinase 1Homo sapiens (human)0.1159
Cyclin-dependent kinase 4Homo sapiens (human)0.1589
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.1464
G2/mitotic-specific cyclin-BMarthasterias glacialis (spiny starfish)0.2067
Protein kinase C alpha typeHomo sapiens (human)6.2667
Glycogen synthase kinase-3 betaRattus norvegicus (Norway rat)0.185
Cyclin-A2Homo sapiens (human)0.3441
Dual specificity protein kinase CLK1Mus musculus (house mouse)1.3
G1/S-specific cyclin-D1Homo sapiens (human)0.1837
Protein kinase C eta typeHomo sapiens (human)8
G1/S-specific cyclin-E1Homo sapiens (human)0.2249
Cyclin-dependent kinase 2Homo sapiens (human)0.2367
G1/S-specific cyclin-D2Homo sapiens (human)0.1
G1/S-specific cyclin-D3Homo sapiens (human)0.1983
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.4
Protein kinase C iota typeHomo sapiens (human)8
Glycogen synthase kinase-3 alphaHomo sapiens (human)0.525
Glycogen synthase kinase-3 betaHomo sapiens (human)0.6517
Cyclin-dependent kinase 7Homo sapiens (human)0.3365
Cyclin-dependent kinase 9Homo sapiens (human)0.0209
Cyclin-HHomo sapiens (human)0.3413
CDK-activating kinase assembly factor MAT1Homo sapiens (human)0.514
Cyclin-A1Homo sapiens (human)0.785
Cyclin-dependent kinase 6Homo sapiens (human)0.1572
Cyclin-dependent-like kinase 5 Homo sapiens (human)0.1747
Cyclin homologHerpesvirus saimiri (strain 11)0.185
Protein kinase C epsilon typeHomo sapiens (human)5.4933
Protein kinase C theta typeHomo sapiens (human)8
Protein kinase C zeta typeHomo sapiens (human)8
Protein kinase C delta typeHomo sapiens (human)5.63
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)0.1765
Serine/threonine-protein kinase D1Homo sapiens (human)8
Dual specificity tyrosine-phosphorylation-regulated kinase 1ARattus norvegicus (Norway rat)0.3
G2/mitotic-specific cyclin-B3Homo sapiens (human)0.1571
Cyclin-dependent kinase 1Oryzias latipes (Japanese medaka)0.2067
Cyclin-dependent kinase 12Homo sapiens (human)1.37

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Russu, WA; Shallal, HM1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1

Other Studies

5 other study(ies) available for ruboxistaurin and alvocidib

ArticleYear
A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nature biotechnology, 2005, Volume: 23, Issue:3

    Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines

2005
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017